Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Wall Street Zen

Posted by Geri Gentry on Aug 10th, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other analysts have also recently issued research reports about the company. Weiss Ratings upgraded Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Citigroup increased their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.55.

Check Out Our Latest Research Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $2.47 on Friday. Lexicon Pharmaceuticals has a 52-week low of $1.02 and a 52-week high of $2.68. The stock’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $1.86. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -16.47 and a beta of 1.08.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The business had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $3.99 million. Equities research analysts expect that Lexicon Pharmaceuticals will post -0.17 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Siren L.L.C. boosted its stake in shares of Lexicon Pharmaceuticals by 13.8% in the first quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock valued at $69,113,000 after purchasing an additional 5,384,615 shares during the period. UBS Group AG grew its holdings in Lexicon Pharmaceuticals by 752.1% during the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 2,654,315 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Lexicon Pharmaceuticals during the 3rd quarter worth $3,240,000. Millennium Management LLC increased its stake in Lexicon Pharmaceuticals by 133.1% during the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock worth $5,171,000 after buying an additional 2,187,396 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Lexicon Pharmaceuticals by 508.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock worth $2,497,000 after buying an additional 1,337,246 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Trending Headlines about Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

Positive Sentiment: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, exceeding its 500-patient enrollment target. Top-line results remain expected in the first quarter of 2027, providing a potentially significant future catalyst. Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Positive Sentiment: The company said its activities to resubmit the ZYNQUISTA NDA for glycemic control in adults with type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026. Phase 1 development of obesity candidate LX9851 is also continuing through partner Novo Nordisk, and Lexicon could receive an additional $10 million milestone payment as early as later this year. Lexicon Pharmaceuticals Q2 2026 Earnings Call Transcript
Positive Sentiment: Lexicon reported $190.6 million in cash and investments at June 30, supported by $96.2 million in stock-sale proceeds, giving it additional resources to fund clinical development. A Hercules Capital facility also provides up to $100 million in potential financing, subject to conditions.
Neutral Sentiment: Management emphasized disciplined capital allocation and early commercial planning for its late-stage pipeline. However, the principal value drivers remain dependent on successful clinical results and regulatory approval.
Negative Sentiment: Second-quarter revenue fell to approximately $0.7 million from $28.9 million a year earlier because the prior-year period included substantial Novo Nordisk licensing revenue. The company posted a net loss of roughly $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter. Revenue also came in below analyst expectations, while research and development spending rose to $17.4 million as SONATA-HCM costs increased. Lexicon Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.